Why Biomarker Strategies Fail: Lessons for Building Global Precision Medicine & CDx Programs

• Precision medicine programs increasingly rely on biomarkers to identify the right patients, demonstrate biological activity, and support clinical decision-making. Yet many biomarker strategies encounter significant challenges as programs move from early development into larger global clinical trials
• This presentation identifies common pitfalls that can compromise biomarker-driven clinical development programs.
• It will explain the importance of harmonization across laboratories, assays, and geographies
• Explores fit-for-purpose approaches for biomarker assay development, validation, and global implementation
• Examines considerations for transitioning from exploratory biomarker strategies toward CDx readiness

Speakers:

Naveen Babbar

Vice President - Scientific Affairs

ICON